Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7012285

CN1CCN(C2CCN(C(=O)[C@H](N)Cc3cc(Br)c(N)c(Br)c3)CC2)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 6/20 0.47
RAMP1 O60894 1/20 0.41
CALCRL Q16602 1/20 0.41
CHRM1 P11229 2/20 0.39
DPP7 Q9UHL4 5/20 0.39
OPRD1 P41143 2/20 0.39
SMYD3 Q9H7B4 3/20 0.38
ALOX15 P16050 1/20 0.36
AKT1 P31749 1/20 0.36
OPRK1 P41145 1/20 0.36
HDAC8 Q9BY41 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7008582 0.90 DPP4 (0.48) DPP4CALCRLCHRM1DPP7OPRD1
SCHEMBL7006555 0.89 L3MBTL3 (0.41) RAMP1CALCRLCHRM1OPRD1SMYD3
SCHEMBL7014034 0.85 CALCRL (0.43) RAMP1CALCRLCHRM1OPRD1SMYD3
SCHEMBL3960017 0.82 DPP8 (0.47) CALCRLCHRM1SMYD3ALOX15
Trifluoroacetic Acid SCHEMBL7011220 0.82 DPP4 (0.48) DPP4CALCRLCHRM1DPP7OPRD1
SCHEMBL7013786 0.81 CALCRL (0.42) RAMP1CALCRLCHRM1OPRD1SMYD3
SCHEMBL7008363 0.81 SMYD3 (0.43) DPP4OPRD1SMYD3AKT1OPRK1
SCHEMBL3311183 0.80 OPRK1 (0.39) RAMP1CALCRLCHRM1OPRD1SMYD3
SCHEMBL29496465 0.80 CHRM1 (0.58) DPP4CHRM1OPRD1ALOX15OPRK1
SCHEMBL5248991 0.80 RAMP1 (0.59) DPP4RAMP1CALCRLCHRM1DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1163239-B1 MODIFIED AMINO-ACID AMIDES AS CGRP ANTAGONISTS BOEHRINGER INGELHEIM PHARMA (DE) 2003-05-28 EP disclosed
US-6313097-B1 TREATMENT OR PROPHYLAXIS OF MIGRAINE OR CLUSTER HEADACHES, NON-INSULIN-DEPENDENT DIABETES MELLITUS, INFLAMMATION, ALLERGIC RHINITIS, ASTHMA, MORPHINE TOLERANCE, MENOPAUSAL HOT FLASHES, DISEASES CHARACTERIZED BY EXCESSIVE VASODILATATION BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-11-06 US disclosed